Welcome to the Inaugural Hippo Pathway Targeted Drug Development Summit

It has been long understood that the Hippo pathway plays a critical role in the development of a wide range of diseases. With the clear therapeutic potential of this highly attractive and targetable pathway, investment, collaboration, and interest in targeting the Hippo pathway has flooded through biopharma and academia, and a once unexploited pathway is now seeing an abundance of promising therapeutic interventions.

As a once elusive pathway, emerging novel data and literature is forging a wider and more developed mechanistic understanding of this valuable signaling pathway, opening new avenues to evolve the landscape of targetable nodes and therapeutic interventions, from small molecule approaches to novel modalities to target the TEAD transcription complex. The inaugural Hippo Pathway Targeted Drug Development Summit has been established as the first and only industry dedicated forum, focussed on accelerating the mechanistic understanding and potentials of the Hippo signaling pathway to enhance the discovery, translation and clinical development of safe and effective drugs in oncology, regenerative medicine and beyond.

Uniting the leading minds of large pharma, biotech and academia, this unrivalled conference will showcase the pioneering discoveries, critical novel findings and promising clinical candidates drugging YAP, TAZ & TEAD transcription factors and other high-value targets within the Hippo pathway, as we dive into:

Innovative case-studies that lead to a better understanding of the Hippo pathway 

How to streamline successful translation of candidates through the clinic & to the patient which is safe & effective

Insights to augment ideal patient selection & how to utilise biomarkers to guide drug development 

Benchmarking modalities to drug the Hippo pathway, from small molecules inhibition and other ovel approaches

Selectivity & toxicity of TEAD, YAP & other high-value target inhibitors as a promising therapeutic 

The value of leveraging the Hippo pathway for the crosstalk in associated pathways such as RAS, EGFR & PI3K

As this industry continues to unlock critical pieces of the puzzle in the understanding and exploiting this signaling pathway, join leading Translational Scientists, Pharmacologists, and Medicinal Chemists as we unite to learn, debate, discuss, and maximally leverage the therapeutic opportunity of this pathway to address the huge unmet clinical need.

2022 World-Class Speaker Faculty Included:

2022 Attendee Snapshot:

Attendee Speaker Company Logos - Hippo

Other Events In The Undruggable Series